Talphera Inc. (TLPH) - Net Assets
Based on the latest financial reports, Talphera Inc. (TLPH) has net assets worth $19.18 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($30.74 Million) and total liabilities ($11.56 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check TLPH asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $19.18 Million |
| % of Total Assets | 62.38% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -75.84% |
| Growth Volatility | 359.91 |
Talphera Inc. - Net Assets Trend (2008–2024)
This chart illustrates how Talphera Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore how large is Talphera Inc.'s balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Talphera Inc. (2008–2024)
The table below shows the annual net assets of Talphera Inc. from 2008 to 2024. For live valuation and market cap data, see TLPH market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $8.00 Million | -43.28% |
| 2023-12-31 | $14.11 Million | -35.34% |
| 2022-12-31 | $21.81 Million | +160.78% |
| 2021-12-31 | $-35.89 Million | +35.62% |
| 2020-12-31 | $-55.75 Million | -34.60% |
| 2019-12-31 | $-41.42 Million | -1073.85% |
| 2018-12-31 | $4.25 Million | +111.65% |
| 2017-12-31 | $-36.51 Million | -584.07% |
| 2016-12-31 | $-5.34 Million | -116.12% |
| 2015-12-31 | $33.11 Million | -29.03% |
| 2014-12-31 | $46.66 Million | -36.23% |
| 2013-12-31 | $73.16 Million | +116.15% |
| 2012-12-31 | $33.85 Million | +93.77% |
| 2011-12-31 | $17.47 Million | +126.51% |
| 2010-12-31 | $-65.89 Million | -24.34% |
| 2009-12-31 | $-52.99 Million | -58.97% |
| 2008-12-31 | $-33.34 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Talphera Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 42313000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $17.00K | 0.21% |
| Other Components | $465.21 Million | 5814.45% |
| Total Equity | $8.00 Million | 100.00% |
Talphera Inc. Competitors by Market Cap
The table below lists competitors of Talphera Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kanoria Chemicals & Industries Limited
NSE:KANORICHEM
|
$41.54 Million |
|
Mondi PLC
LSE:MNDI
|
$41.55 Million |
|
Nusa Konstruksi Enjiniring Tbk
JK:DGIK
|
$41.57 Million |
|
GFG Resources Inc
V:GFG
|
$41.58 Million |
|
Lider Faktoring AS
IS:LIDFA
|
$41.52 Million |
|
Doctor Care Anywhere Group Plc
AU:DOC
|
$41.51 Million |
|
Canlan Ice Sports Corp.
TO:ICE
|
$41.49 Million |
|
Panorama Sentrawisata Tbk
JK:PANR
|
$41.46 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Talphera Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 14,105,000 to 8,000,999, a change of -6,104,001 (-43.3%).
- Net loss of 13,004,000 reduced equity.
- Other factors increased equity by 6,899,999.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-13.00 Million | -162.53% |
| Other Changes | $6.90 Million | +86.24% |
| Total Change | $- | -43.28% |
Book Value vs Market Value Analysis
This analysis compares Talphera Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.97x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | $-32.41 | $0.92 | x |
| 2009-12-31 | $-51.52 | $0.92 | x |
| 2010-12-31 | $-64.06 | $0.92 | x |
| 2011-12-31 | $20.14 | $0.92 | x |
| 2012-12-31 | $30.60 | $0.92 | x |
| 2013-12-31 | $36.81 | $0.92 | x |
| 2014-12-31 | $21.05 | $0.92 | x |
| 2015-12-31 | $14.89 | $0.92 | x |
| 2016-12-31 | $-2.36 | $0.92 | x |
| 2017-12-31 | $-15.57 | $0.92 | x |
| 2018-12-31 | $1.46 | $0.92 | x |
| 2019-12-31 | $-10.46 | $0.92 | x |
| 2020-12-31 | $-13.08 | $0.92 | x |
| 2021-12-31 | $-5.99 | $0.92 | x |
| 2022-12-31 | $2.95 | $0.92 | x |
| 2023-12-31 | $0.99 | $0.92 | x |
| 2024-12-31 | $0.31 | $0.92 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Talphera Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -162.53%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.28x
- Recent ROE (-162.53%) is below the historical average (-93.97%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $-17.33 Million |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-14.82 Million |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.75 Million |
| 2011 | -115.07% | -1875.09% | 0.03x | 2.34x | $-21.85 Million |
| 2012 | -98.57% | -1393.61% | 0.04x | 1.91x | $-36.75 Million |
| 2013 | -32.02% | -79.40% | 0.27x | 1.50x | $-30.74 Million |
| 2014 | -71.49% | -639.31% | 0.06x | 1.85x | $-38.02 Million |
| 2015 | -73.68% | -126.66% | 0.15x | 3.86x | $-27.71 Million |
| 2016 | 0.00% | -248.64% | 0.17x | 0.00x | $-42.62 Million |
| 2017 | 0.00% | -644.25% | 0.11x | 0.00x | $-47.86 Million |
| 2018 | -1108.61% | -2191.96% | 0.02x | 28.34x | $-47.57 Million |
| 2019 | 0.00% | -2325.91% | 0.03x | 0.00x | $-49.10 Million |
| 2020 | 0.00% | -745.55% | 0.08x | 0.00x | $-34.80 Million |
| 2021 | 0.00% | -9285.45% | 0.00x | 0.00x | $-31.51 Million |
| 2022 | 194.90% | 2400.62% | 0.04x | 2.18x | $40.33 Million |
| 2023 | -130.43% | -2825.96% | 0.03x | 1.45x | $-19.81 Million |
| 2024 | -162.53% | 0.00% | 0.00x | 2.28x | $-13.80 Million |
Industry Comparison
This section compares Talphera Inc.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $236,113,024
- Average return on equity (ROE) among peers: -47.06%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Talphera Inc. (TLPH) | $19.18 Million | 0.00% | 0.60x | $41.54 Million |
| Aurora Cannabis Inc (ACB) | $602.92 Million | -11.50% | 0.39x | $197.35 Million |
| Akanda Corp (AKAN) | $-3.83 Million | 0.00% | 0.00x | $1.51 Million |
| Akebia Ther (AKBA) | $74.01 Million | -330.87% | 6.15x | $340.21 Million |
| Alkermes Plc (ALKS) | $54.20 Million | -73.99% | 0.03x | $4.62 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $-25.36 Million | 0.00% | 0.00x | $1.77 Billion |
| Amphastar P (AMPH) | $639.42 Million | 21.51% | 1.37x | $959.02 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $346.79 Million | -104.36% | 9.57x | $3.81 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $344.93 Million | 26.40% | 10.61x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $287.08 Million | 1.44% | 0.21x | $199.00 Million |
| ANI Pharmaceuticals Inc (ANIP) | $40.96 Million | 0.73% | 0.09x | $1.80 Billion |
About Talphera Inc.
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, a nafamostat formulat… Read more